{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:11:08Z","timestamp":1791810668536,"version":"4.3.4"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T00:00:00Z","timestamp":1646697600000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2022,2,11]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This post hoc analysis assessed speed, magnitude and maintenance of pain improvement in patients with early rheumatoid arthritis (RA) receiving baricitinib, baricitinib and methotrexate (MTX), or MTX over 1\u2009year. Cumulative pain and quality of life benefits were also assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Randomised, double-blind, phase 3 study RA-BEGIN (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01711359\">NCT01711359<\/jats:ext-link>) compared baricitinib 4\u2009mg (N=159), baricitinib 4\u2009mg +MTX (N=215) and MTX (N=210) in patients with RA who had no or limited prior disease-modifying antirheumatic drug treatment. Pain was assessed on a 0\u2013100\u2009mm Visual Analogue Scale (VAS). Proportion of patients with \u226530%, \u226550% and \u226570%\u2009pain improvement from baseline; \u226420\u2009mm and \u226410\u2009mm on the pain VAS; and time to achieve pain improvement thresholds were assessed over 52 weeks, as were Patient Global Assessment (PtGA) and 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS) outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baricitinib monotherapy or combination with MTX provides greater (least square mean changes (LSM) from baseline \u221240\u2009mm and \u221243\u2009mm, respectively) and more rapid (median 12 and 8 weeks to \u226570% improvement, respectively) pain relief than MTX alone (LSM \u221231\u2009mm, median 20 weeks to \u226570% improvement) over 52 weeks. Baricitinib, alone or combination, provides 9\u201310 additional weeks of limited to no pain, similar gain in achievable wellness measured through PtGA, and 5\u20137 additional weeks with change in SF-36 PCS \u22655 vs MTX over 1\u2009year.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Patients treated with baricitinib reported significantly greater and more rapid pain relief, more weeks with limited to no pain, and clinically meaningful improvements in physical health than patients treated with MTX alone over 1\u2009year.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2021-001994","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T11:19:34Z","timestamp":1646824774000},"page":"e001994","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":29,"title":["Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct01711359","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01711359","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7766-6167","authenticated-orcid":false,"given":"Peter C.","family":"Taylor","sequence":"first","affiliation":[{"name":"Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-4412","authenticated-orcid":false,"given":"Rieke","family":"Alten","sequence":"additional","affiliation":[{"name":"Internal Medicine II, Rheumatology, SCHLOSSPARK-KLINIK, University Medicine Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"\u00c1lvaro Gracia","sequence":"additional","affiliation":[{"name":"Rheumatology Department, Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad","family":"Walls","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6705-8045","authenticated-orcid":false,"given":"Amanda","family":"Quebe","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bochao","family":"Jia","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bello","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ross","family":"Terres","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6630-1477","authenticated-orcid":false,"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[{"name":"Metroplex Clinical Research Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,9]]},"reference":[{"key":"2025090313173728000_8.1.e001994.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121248"},{"key":"2025090313173728000_8.1.e001994.2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.22790","article-title":"Remaining pain in early rheumatoid arthritis patients treated with methotrexate","volume":"68","author":"Altawil","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090313173728000_8.1.e001994.3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/14397595.2017.1416940","article-title":"Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review","volume":"28","author":"Ishida","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2025090313173728000_8.1.e001994.4","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1002\/art.39238","article-title":"Determining pathways to improvements in fatigue in rheumatoid arthritis: results from the British Society for rheumatology biologics register for rheumatoid arthritis","volume":"67","author":"Druce","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313173728000_8.1.e001994.5","first-page":"231","article-title":"Health-Related quality of life in early rheumatoid arthritis: impact of disease and treatment response","volume":"8","author":"Kosinski","year":"2002","journal-title":"Am J Manag Care"},{"key":"2025090313173728000_8.1.e001994.6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.305.6846.160"},{"key":"2025090313173728000_8.1.e001994.7","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"2025090313173728000_8.1.e001994.8","first-page":"S43","article-title":"The consequences of rheumatoid arthritis: quality of life measures in the individual patient","volume":"23","author":"Pollard","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313173728000_8.1.e001994.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019935"},{"key":"2025090313173728000_8.1.e001994.10","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200002)43:2<386::AID-ANR19>3.0.CO;2-Z"},{"key":"2025090313173728000_8.1.e001994.11","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1177\/147323001003800402","article-title":"Patient perceptions concerning pain management in the treatment of rheumatoid arthritis","volume":"38","author":"Taylor","year":"2010","journal-title":"J Int Med Res"},{"key":"2025090313173728000_8.1.e001994.12","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/acr.22824","article-title":"Unraveling patient-preferred health and treatment outcomes in early rheumatoid arthritis: a longitudinal qualitative study","volume":"68","author":"van der Elst","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2025090313173728000_8.1.e001994.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2011.08.001"},{"key":"2025090313173728000_8.1.e001994.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.64"},{"key":"2025090313173728000_8.1.e001994.15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11914-018-0473-5","article-title":"Mechanisms for joint pain in rheumatoid arthritis (rA): from cytokines to central sensitization","volume":"16","author":"Zhang","year":"2018","journal-title":"Curr Osteoporos Rep"},{"key":"2025090313173728000_8.1.e001994.16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.semarthrit.2020.10.008","article-title":"The JAK\/STAT pathway: a focus on pain in rheumatoid arthritis","volume":"51","author":"Simon","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313173728000_8.1.e001994.17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2025090313173728000_8.1.e001994.18","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.3390\/jcm8091394","article-title":"Effect of baricitinib and adalimumab in reducing pain and improving function in patients with rheumatoid arthritis in low disease activity: exploratory analyses from RA-BEAM","volume":"8","author":"Fautrel","year":"2019","journal-title":"J Clin Med"},{"key":"2025090313173728000_8.1.e001994.19","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s13075-017-1410-1","article-title":"Patient-Reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"19","author":"Schiff","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"2025090313173728000_8.1.e001994.20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"JCM"},{"key":"2025090313173728000_8.1.e001994.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"2025090313173728000_8.1.e001994.22","first-page":"2016","article-title":"Minimal disease activity for rheumatoid arthritis: a preliminary definition","volume":"32","author":"Wells","year":"2005","journal-title":"J Rheumatol"},{"key":"2025090313173728000_8.1.e001994.23","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21747"},{"key":"2025090313173728000_8.1.e001994.24","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025090313173728000_8.1.e001994.25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"2025090313173728000_8.1.e001994.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pain.2009.08.019"},{"key":"2025090313173728000_8.1.e001994.27","first-page":"1674","article-title":"Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"34","author":"Wolfe","year":"2007","journal-title":"J Rheumatol"},{"key":"2025090313173728000_8.1.e001994.28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s13075-020-02324-7","article-title":"Associations between patient global assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib","volume":"22","author":"Strand","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2025090313173728000_8.1.e001994.29","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20685"},{"key":"2025090313173728000_8.1.e001994.30","doi-asserted-by":"publisher","DOI":"10.1002\/art.34543"},{"key":"2025090313173728000_8.1.e001994.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205489"},{"key":"2025090313173728000_8.1.e001994.32","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.200758"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2021-001994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:17:49Z","timestamp":1756930669000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2021-001994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,3,9]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/rmdopen-2021-001994"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2021-001994","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}